Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
BMY · NYSE · Pharmaceutical Preparations
Fundamental quality
74
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
On average over recent years, earnings per share grew 6.1% a year and revenue advanced 1.5% a year.
On profitability, Bristol Myers Squibb Co shows a net margin of 15%, a gross margin of 63.4%, an ROE of 36.3%.
Its financial health shows a free cash flow margin of 24.6%.
Adding up growth, profitability and financial strength, the traffic light gives BMY a fundamental quality of 74 out of 100. To also know whether it's cheap or expensive, the price is missing: enter it in the tool and you'll get the valuation verdict (P/E against its sector).
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Bristol Myers Squibb Co cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →